JP2019504057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504057A5 JP2019504057A5 JP2018534682A JP2018534682A JP2019504057A5 JP 2019504057 A5 JP2019504057 A5 JP 2019504057A5 JP 2018534682 A JP2018534682 A JP 2018534682A JP 2018534682 A JP2018534682 A JP 2018534682A JP 2019504057 A5 JP2019504057 A5 JP 2019504057A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- seq
- isolated peptide
- gln
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0191082 | 2015-12-31 | ||
| KR20150191082 | 2015-12-31 | ||
| KR20160163737 | 2016-12-02 | ||
| KR10-2016-0163737 | 2016-12-02 | ||
| PCT/KR2016/015554 WO2017116204A1 (ko) | 2015-12-31 | 2016-12-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020093904A Division JP7030894B2 (ja) | 2015-12-31 | 2020-05-29 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504057A JP2019504057A (ja) | 2019-02-14 |
| JP2019504057A5 true JP2019504057A5 (https=) | 2019-11-28 |
| JP6712323B2 JP6712323B2 (ja) | 2020-06-17 |
Family
ID=59225193
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534682A Active JP6712323B2 (ja) | 2015-12-31 | 2016-12-30 | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| JP2018534662A Active JP6712322B2 (ja) | 2015-12-31 | 2016-12-30 | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 |
| JP2020093904A Active JP7030894B2 (ja) | 2015-12-31 | 2020-05-29 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| JP2020093915A Active JP7526039B2 (ja) | 2015-12-31 | 2020-05-29 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 |
| JP2022109549A Pending JP2022130723A (ja) | 2015-12-31 | 2022-07-07 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534662A Active JP6712322B2 (ja) | 2015-12-31 | 2016-12-30 | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 |
| JP2020093904A Active JP7030894B2 (ja) | 2015-12-31 | 2020-05-29 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| JP2020093915A Active JP7526039B2 (ja) | 2015-12-31 | 2020-05-29 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 |
| JP2022109549A Pending JP2022130723A (ja) | 2015-12-31 | 2022-07-07 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US10370426B2 (https=) |
| EP (3) | EP3398961B1 (https=) |
| JP (5) | JP6712323B2 (https=) |
| KR (8) | KR20170080522A (https=) |
| CN (6) | CN109071624B (https=) |
| AU (4) | AU2016382394B2 (https=) |
| BR (1) | BR112018013530A2 (https=) |
| CA (2) | CA3010182A1 (https=) |
| CL (6) | CL2018001776A1 (https=) |
| CO (2) | CO2018006986A2 (https=) |
| CR (2) | CR20180380A (https=) |
| DK (1) | DK3398961T3 (https=) |
| DO (2) | DOP2018000157A (https=) |
| EA (2) | EA038524B1 (https=) |
| EC (2) | ECSP18053055A (https=) |
| ES (1) | ES2925098T3 (https=) |
| HK (1) | HK1258177A1 (https=) |
| HR (1) | HRP20220995T1 (https=) |
| HU (1) | HUE059737T2 (https=) |
| IL (2) | IL260318B2 (https=) |
| MX (2) | MX2018008027A (https=) |
| PE (2) | PE20250556A1 (https=) |
| PH (2) | PH12018501409B1 (https=) |
| PL (1) | PL3398961T3 (https=) |
| PT (1) | PT3398961T (https=) |
| RS (1) | RS63541B1 (https=) |
| SA (2) | SA518391891B1 (https=) |
| SG (2) | SG11201805586SA (https=) |
| TN (2) | TN2018000228A1 (https=) |
| TW (4) | TWI731015B (https=) |
| WO (2) | WO2017116204A1 (https=) |
| ZA (2) | ZA201804997B (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
| MY185334A (en) | 2014-12-30 | 2021-05-06 | Hanmi Pharm Ind Co Ltd | Glucagon derivatives with improved stability |
| EA201890058A1 (ru) | 2015-06-30 | 2018-07-31 | Ханми Фарм. Ко., Лтд. | Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного |
| WO2017116204A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
| KR102005457B1 (ko) | 2016-06-29 | 2019-07-30 | 한미약품 주식회사 | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 |
| JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
| CN110545852B (zh) | 2017-02-07 | 2023-05-26 | 韩美药品株式会社 | 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法 |
| CN110637027B (zh) | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| TWI912614B (zh) | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN109239346B (zh) * | 2018-10-31 | 2019-10-11 | 中国药科大学 | 一组代谢标志物在代谢综合征早期诊断方面的应用 |
| WO2020130749A1 (ko) | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 |
| EP3939990A4 (en) * | 2019-02-15 | 2023-05-24 | Hanmi Fine Chemical Co., Ltd. | NOVEL INTERMEDIATE FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND PROCESS FOR THE PRODUCTION THEREOF |
| WO2020214013A1 (ko) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 |
| WO2020214012A1 (ko) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| DK3936142T3 (da) * | 2019-06-28 | 2024-03-25 | Hanmi Pharmaceutical Co Ltd | Tredobbelt agonist med aktivitet med hensyn til alle glucagon-, GLP-1- og GLP-receptorer til behandling af leversygdom |
| MX2022002115A (es) | 2019-08-19 | 2022-03-17 | Lilly Co Eli | Metodos para preparar analogos de incretina. |
| WO2021066600A1 (ko) * | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| EP4058047A1 (en) | 2019-11-11 | 2022-09-21 | Boehringer Ingelheim International GmbH | Npy2 receptor agonists |
| TWI795698B (zh) | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN111040022B (zh) * | 2019-12-23 | 2021-12-14 | 万新医药科技(苏州)有限公司 | 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂 |
| CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| PE20221595A1 (es) * | 2020-01-13 | 2022-10-10 | Hanmi Pharm Ind Co Ltd | Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| BR112022020531A2 (pt) * | 2020-04-20 | 2022-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| MX2022014670A (es) * | 2020-05-22 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Formulacion liquida. |
| BR112022023609A2 (pt) * | 2020-05-22 | 2023-02-07 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado de ação prolongada de agonista trigonal de glucagon, glp-1 e gip |
| BR112023000585A2 (pt) | 2020-07-17 | 2023-03-28 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica e uso da mesma |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| EP4197550A4 (en) * | 2020-08-14 | 2025-10-08 | Hanmi Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS |
| MX2023001599A (es) | 2020-08-14 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip. |
| CN116419766A (zh) | 2020-09-25 | 2023-07-11 | 韩美药品株式会社 | 作用于胰高血糖素、glp-1和gip受体全部的三重激动剂的长效缀合物对抗多发性硬化的治疗用途 |
| KR20220041765A (ko) | 2020-09-25 | 2022-04-01 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물 |
| JP2023543036A (ja) * | 2020-09-25 | 2023-10-12 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途 |
| CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| WO2022080985A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Gip 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2022080987A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물 |
| WO2022080984A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| KR20220050824A (ko) * | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도 |
| US20230381281A1 (en) * | 2020-10-16 | 2023-11-30 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases |
| EP4236991A1 (en) | 2020-10-30 | 2023-09-06 | Novo Nordisk A/S | Glp-1, gip and glucagon receptor triple agonists |
| EP4257597A4 (en) * | 2020-12-02 | 2025-04-02 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS |
| US20230382974A1 (en) * | 2020-12-24 | 2023-11-30 | Hanmi Pharm. Co., Ltd. | Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use thereof |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| JP2024505943A (ja) * | 2021-01-29 | 2024-02-08 | ハンミ ファーマシューティカルズ カンパニー リミテッド | Ｇｉｐ誘導体、またはその持続型結合体を含む肺疾患の予防用または治療用の薬学的組成物 |
| US20250129135A1 (en) | 2021-05-26 | 2025-04-24 | The United Bio-Technology (Hengqin) Co., Ltd | Multi-Agonist and Use Thereof |
| KR20230004135A (ko) | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| TW202313667A (zh) * | 2021-07-30 | 2023-04-01 | 大陸商南京明德新藥研發有限公司 | 含內醯胺橋的多肽化合物 |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| KR20230095665A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 약물 및 이의 용도 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| EP4323413A4 (en) | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| AU2023276018A1 (en) * | 2022-05-27 | 2024-11-21 | D&D Pharmatech Inc. | Peptide compositions and methods of use threof |
| IL321555B1 (en) | 2022-12-23 | 2026-01-01 | Hanmi Pharmaceutical Co Ltd | A novel triple agonist for glp-1/gip/glucagon and a pharmaceutical preparation containing it for the prevention or treatment of obesity |
| PE20252287A1 (es) | 2023-01-31 | 2025-09-18 | Lilly Co Eli | Agonistas del trirreceptor gip/glp1/gcg y usos de estos |
| EP4724471A1 (en) | 2023-06-09 | 2026-04-15 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| WO2025259064A1 (ko) * | 2024-06-13 | 2025-12-18 | 한미약품 주식회사 | Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물 |
| WO2025259063A1 (ko) * | 2024-06-13 | 2025-12-18 | 한미약품 주식회사 | Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물 |
| WO2025259060A1 (ko) * | 2024-06-13 | 2025-12-18 | 한미약품 주식회사 | Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물 |
| WO2025259062A1 (ko) * | 2024-06-13 | 2025-12-18 | 한미약품 주식회사 | Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 신장 질환의 예방 또는 치료용 약학적 조성물 |
| CN120189527B (zh) * | 2025-05-27 | 2026-04-03 | 广州富肽生物有限公司 | 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5476304A (en) | 1977-11-29 | 1979-06-18 | Tokyo Printing Ink Mfg Co Ltd | Ink |
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| DK1143989T3 (da) * | 1999-01-14 | 2007-04-16 | Amylin Pharmaceuticals Inc | Exendiner til glucagonundertrykkelse |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| ATE424413T1 (de) * | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
| EP1411968B1 (en) * | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| EP1605897B1 (en) * | 2003-03-19 | 2012-07-25 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
| JP2007537981A (ja) * | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| ATE555133T1 (de) | 2003-11-13 | 2012-05-15 | Hanmi Holdings Co Ltd | Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung |
| US20080027072A1 (en) * | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
| ES2495741T3 (es) * | 2006-04-20 | 2014-09-17 | Amgen, Inc | Compuestos de GLP-1 |
| RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| TWI423821B (zh) | 2007-06-19 | 2014-01-21 | Glucose-containing glucagon-like peptide-1 peptide | |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| EP2300037B1 (en) * | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112012018104A2 (pt) | 2010-01-20 | 2017-10-17 | Zeland Pharma As | tratamento de doenças cardíacas |
| EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| JP5812627B2 (ja) * | 2010-03-10 | 2015-11-17 | 公益財団法人相模中央化学研究所 | 改良Ｆｃ受容体およびその製造方法 |
| EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| US8507428B2 (en) * | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| KR20240110072A (ko) | 2011-05-18 | 2024-07-12 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| PE20240686A1 (es) | 2011-06-10 | 2024-04-10 | Hanmi Science Co Ltd | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) |
| PE20230404A1 (es) | 2011-06-17 | 2023-03-07 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
| BR112013032717A2 (pt) * | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| RS56173B1 (sr) * | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
| WO2013170636A1 (zh) | 2012-05-18 | 2013-11-21 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| HRP20180936T1 (hr) * | 2012-06-21 | 2018-12-14 | Indiana University Research And Technology Corporation | Analozi glukagona koji pokazuju aktivnost prema receptoru za gip |
| TW201402611A (zh) * | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| PE20151421A1 (es) | 2012-11-06 | 2015-09-24 | Hanmi Pharm Ind Co Ltd | Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| DK2922877T3 (da) | 2012-11-20 | 2019-01-02 | Eumederis Pharmaceuticals Inc | Forbedrede peptidlægemidler |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| HK1211232A1 (en) * | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| CN105324125A (zh) * | 2013-03-15 | 2016-02-10 | 印第安纳大学研究及科技有限公司 | 具有长效的前体药物 |
| SI2986313T1 (sl) | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| HK1226084A1 (zh) | 2013-08-16 | 2017-09-22 | Medimmune Limited | 用於治疗糖尿病的gip和glp-1受体双重激动剂 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| ES2822994T3 (es) * | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
| MY185334A (en) | 2014-12-30 | 2021-05-06 | Hanmi Pharm Ind Co Ltd | Glucagon derivatives with improved stability |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| EA201890058A1 (ru) | 2015-06-30 | 2018-07-31 | Ханми Фарм. Ко., Лтд. | Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного |
| TW201718629A (zh) | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| KR20170065016A (ko) | 2015-12-02 | 2017-06-12 | 한미약품 주식회사 | 지방산 유도체를 이용한 단백질 결합체 및 이의 제조방법 |
| WO2017116204A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
-
2016
- 2016-12-30 WO PCT/KR2016/015554 patent/WO2017116204A1/ko not_active Ceased
- 2016-12-30 JP JP2018534682A patent/JP6712323B2/ja active Active
- 2016-12-30 BR BR112018013530-5A patent/BR112018013530A2/pt active Search and Examination
- 2016-12-30 JP JP2018534662A patent/JP6712322B2/ja active Active
- 2016-12-30 CN CN201680082339.8A patent/CN109071624B/zh active Active
- 2016-12-30 MX MX2018008027A patent/MX2018008027A/es unknown
- 2016-12-30 IL IL260318A patent/IL260318B2/en unknown
- 2016-12-30 DK DK16882156.9T patent/DK3398961T3/da active
- 2016-12-30 TN TNP/2018/000228A patent/TN2018000228A1/en unknown
- 2016-12-30 TW TW105144154A patent/TWI731015B/zh active
- 2016-12-30 PE PE2023002166A patent/PE20250556A1/es unknown
- 2016-12-30 CN CN201680082352.3A patent/CN108699125B/zh active Active
- 2016-12-30 MX MX2018008128A patent/MX2018008128A/es unknown
- 2016-12-30 EP EP16882156.9A patent/EP3398961B1/en active Active
- 2016-12-30 PT PT168821569T patent/PT3398961T/pt unknown
- 2016-12-30 SG SG11201805586SA patent/SG11201805586SA/en unknown
- 2016-12-30 EP EP16882157.7A patent/EP3398962A4/en active Pending
- 2016-12-30 KR KR1020160183500A patent/KR20170080522A/ko not_active Ceased
- 2016-12-30 PH PH1/2018/501409A patent/PH12018501409B1/en unknown
- 2016-12-30 CN CN202211234307.9A patent/CN116063453A/zh active Pending
- 2016-12-30 CN CN202211287482.4A patent/CN116059389A/zh active Pending
- 2016-12-30 RS RS20220774A patent/RS63541B1/sr unknown
- 2016-12-30 TN TNP/2018/000231A patent/TN2018000231A1/en unknown
- 2016-12-30 CA CA3010182A patent/CA3010182A1/en active Pending
- 2016-12-30 CN CN202211656375.4A patent/CN115920077B/zh active Active
- 2016-12-30 HR HRP20220995TT patent/HRP20220995T1/hr unknown
- 2016-12-30 HK HK19100534.2A patent/HK1258177A1/en unknown
- 2016-12-30 TW TW112108994A patent/TWI877582B/zh active
- 2016-12-30 TW TW111101118A patent/TWI807580B/zh active
- 2016-12-30 AU AU2016382394A patent/AU2016382394B2/en active Active
- 2016-12-30 TW TW105144155A patent/TWI800478B/zh active
- 2016-12-30 AU AU2016382393A patent/AU2016382393B2/en active Active
- 2016-12-30 PE PE2018001233A patent/PE20181494A1/es unknown
- 2016-12-30 CN CN202211234594.3A patent/CN116063454A/zh active Pending
- 2016-12-30 PL PL16882156.9T patent/PL3398961T3/pl unknown
- 2016-12-30 PH PH1/2018/501411A patent/PH12018501411B1/en unknown
- 2016-12-30 CR CR20180380A patent/CR20180380A/es unknown
- 2016-12-30 KR KR1020160183499A patent/KR20170080521A/ko not_active Ceased
- 2016-12-30 ES ES16882156T patent/ES2925098T3/es active Active
- 2016-12-30 SG SG11201805573RA patent/SG11201805573RA/en unknown
- 2016-12-30 EA EA201891359A patent/EA038524B1/ru unknown
- 2016-12-30 HU HUE16882156A patent/HUE059737T2/hu unknown
- 2016-12-30 EP EP21201279.3A patent/EP3985017A1/en active Pending
- 2016-12-30 IL IL260310A patent/IL260310B2/en unknown
- 2016-12-30 CA CA3010265A patent/CA3010265C/en active Active
- 2016-12-30 EA EA201891360A patent/EA038544B1/ru unknown
- 2016-12-30 WO PCT/KR2016/015555 patent/WO2017116205A1/ko not_active Ceased
- 2016-12-30 CR CR20180381A patent/CR20180381A/es unknown
-
2018
- 2018-06-25 SA SA518391891A patent/SA518391891B1/ar unknown
- 2018-06-26 SA SA518391903A patent/SA518391903B1/ar unknown
- 2018-06-28 CL CL2018001776A patent/CL2018001776A1/es unknown
- 2018-06-28 DO DO2018000157A patent/DOP2018000157A/es unknown
- 2018-06-29 DO DO2018000159A patent/DOP2018000159A/es unknown
- 2018-06-29 CL CL2018001795A patent/CL2018001795A1/es unknown
- 2018-06-29 US US16/023,994 patent/US10370426B2/en active Active
- 2018-06-29 US US16/024,014 patent/US10400020B2/en active Active
- 2018-07-04 CO CONC2018/0006986A patent/CO2018006986A2/es unknown
- 2018-07-04 CO CONC2018/0006982A patent/CO2018006982A2/es unknown
- 2018-07-13 EC ECSENADI201853055A patent/ECSP18053055A/es unknown
- 2018-07-13 EC ECSENADI201853053A patent/ECSP18053053A/es unknown
- 2018-07-25 ZA ZA2018/04997A patent/ZA201804997B/en unknown
- 2018-07-25 ZA ZA2018/04998A patent/ZA201804998B/en unknown
-
2019
- 2019-01-31 US US16/263,469 patent/US10981967B2/en active Active
- 2019-03-29 US US16/370,057 patent/US11332508B2/en active Active
- 2019-05-27 KR KR1020190061853A patent/KR102401869B1/ko active Active
- 2019-05-27 KR KR1020190061852A patent/KR102367997B1/ko active Active
- 2019-06-04 AU AU2019203891A patent/AU2019203891B2/en active Active
- 2019-06-04 AU AU2019203888A patent/AU2019203888B2/en active Active
- 2019-08-29 KR KR1020190106690A patent/KR102179391B1/ko active Active
- 2019-08-29 KR KR1020190106691A patent/KR102179392B1/ko active Active
-
2020
- 2020-05-29 JP JP2020093904A patent/JP7030894B2/ja active Active
- 2020-05-29 JP JP2020093915A patent/JP7526039B2/ja active Active
- 2020-07-27 KR KR1020200093189A patent/KR102285377B1/ko active Active
- 2020-07-27 KR KR1020200093190A patent/KR102285378B1/ko active Active
- 2020-08-05 CL CL2020002033A patent/CL2020002033A1/es unknown
- 2020-08-05 CL CL2020002034A patent/CL2020002034A1/es unknown
-
2021
- 2021-02-26 US US17/187,098 patent/US20210188937A1/en not_active Abandoned
-
2022
- 2022-03-07 CL CL2022000557A patent/CL2022000557A1/es unknown
- 2022-03-07 CL CL2022000558A patent/CL2022000558A1/es unknown
- 2022-03-21 US US17/700,055 patent/US20220213164A1/en active Pending
- 2022-07-07 JP JP2022109549A patent/JP2022130723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504057A5 (https=) | ||
| JP2019504055A5 (https=) | ||
| PE20231309A1 (es) | Agonistas duales glp-1/gip | |
| JP7554928B2 (ja) | Ｇｌｐ－１およびアミリン受容体の共作動薬 | |
| ES2514615T3 (es) | Proteínas de dominio Kunitz inhibidores de calicreína y ácidos nucleicos que codifican las mismas | |
| JP7030894B2 (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体 | |
| ES2646614T3 (es) | Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad | |
| RU2207874C9 (ru) | Производное инсулина или его физиологически приемлемая соль, предшественник производного инсулина, днк-последовательность, кодирующая предшественник, вектор экспрессии, содержащий упомянутую днк-последовательность, субстрат, трансформированный упомянутым вектором экспрессии, фармацевтическая композиция с понижающей, соответственно регулирующей уровень глюкозы в крови эффективностью | |
| PE20230861A1 (es) | Agonistas dobles de glp-1/gip de accion prolongada | |
| RU2015101697A (ru) | Аналоги глюкагона, обладающие активностью рецептора gip | |
| US10822386B2 (en) | Insulin analogues with enhanced stability and reduced mitogenicity | |
| JP2013542715A5 (https=) | ||
| JP2021521230A5 (https=) | ||
| AR031701A1 (es) | COMPUESTOS ANA LOGOS DEL (GLP-1)-PEPTIDO-1 ANALOGO DEL GLUCAGoN, METODO PARA ESTIMULAR LOS RECEPTORES GLP-1 UTILIZANDO DICHOS COMPUESTOS Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS PARA ESTIMULAR LA SECRECION DE INSULINA | |
| JP2013501818A5 (https=) | ||
| WO2016045400A1 (zh) | 胃泌酸调节素类似物 | |
| PE20190355A1 (es) | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo | |
| JP2012518035A5 (https=) | ||
| CN115181175A (zh) | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 | |
| CN105324397A (zh) | 胰岛素-肠促胰岛素缀合物 | |
| JP2015180647A (ja) | ハロゲン安定化インスリン | |
| EP2804621A1 (en) | Glutamic acid-stabilized insulin analogues | |
| JP2014504588A5 (https=) | ||
| RU2012151296A (ru) | Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность | |
| CN112791178B (zh) | Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化 |